

SECONDARY PHARMACODYNAMIC STUDIES AND *IN VITRO* PHARMACOLOGICAL PROFILING

DUNCAN ARMSTRONG,¹ JACQUES MIGEON,² MICHAEL G. ROLF,¹
JOANNE BOWES,¹ MARK CRAWFORD,² AND JEAN-PIERRE VALENTIN¹

¹*AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, United Kingdom*

²*Cerep, Redmond, Washington*

Contents

- 1 Introduction
 - 1.1 Definitions
 - 1.2 Historical and Regulatory Perspectives
- 2 Drivers for Secondary Pharmacodynamic Studies
 - 2.1 Regulatory Requirements
 - 2.2 Economic Environment
- 3 Approaches to Pharmacological Profiling
 - 3.1 Factors Influencing the Approach to Secondary Pharmacodynamics
 - 3.2 *In Vivo* and *In Vitro* Approaches to Secondary Pharmacodynamics
 - 3.3 Strategies for *In Vitro* Pharmacological Profiling
- 4 Technical Considerations for *In Vitro* Profiling
 - 4.1 Assay Technologies
 - 4.2 *In Vitro* Panel Design
 - 4.3 ADME/PK Profiling
 - 4.4 Data Analysis and Interpretation